Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals

Detalhes bibliográficos
Autor(a) principal: Luna, Tânia
Data de Publicação: 2011
Outros Autores: Santos, Silvane Braga, Nascimento, Marcia Cristina Furtado, Porto, M. Aurélia Fonseca, Santos, André Luiz Muniz Alves dos, Carvalho Filho, Edgar Marcelino de, Jesus, Amélia Maria Ribeiro de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFS
Texto Completo: https://ri.ufs.br/handle/riufs/926
Resumo: Human T lymphotropic virus type 1 (HTLV-1) is the causal agent of myelopathy/tropical spastic paraparesis (HAM/TSP), a disease mediated by the immune response. HTLV-1 induces a spontaneous proliferation and production of pro-inflammatory cytokines by T cells, and increasing interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) levels are potentially involved in tissue damage in diseases related to HTLV-1. This exaggerated immune response is also due to an inability of the natural regulatory mechanisms to down-modulate the immune response in this group of patients. TNF-α inhibitors reduce inflammation and have been shown to improve chronic inflammatory diseases in clinical trials. The aim of this study was to evaluate the ability of pentoxifylline, forskolin, rolipram, and thalidomide to decrease in vitro production of TNF-α and IFN-γ in cells of HTLV-1-infected subjects. Participants of the study included 19 patients with HAM/TSP (mean age, 53 ± 11; male:female ratio, 1:1) and 18 HTLV-1 carriers (mean age, 47 ± 11; male:female ratio, 1:2.6). Cytokines were determined by ELISA in supernatants of mononuclear cell cultures. Pentoxifylline inhibited TNF-α and IFN-γ synthesis with the minimum dose used (50 µM). The results with forskolin were similar to those observed with pentoxifylline. The doses of rolipram used were 0.01-1 µM and the best inhibition of TNF-α production was achieved with 1 µM and for IFN-γ production it was 0.01 µM. The minimum dose of thalidomide used (1 µM) inhibited TNF-α production but thalidomide did not inhibit IFN-γ production even when the maximum dose (50 µM) was used. All drugs had an in vitro inhibitory effect on TNF-α production and, with the exception of thalidomide, all of them also decreased IFN-γ production.
id UFS-2_cdd087b1492d2686a7d3ca95fea6c59d
oai_identifier_str oai:ufs.br:riufs/926
network_acronym_str UFS-2
network_name_str Repositório Institucional da UFS
repository_id_str
spelling Luna, TâniaSantos, Silvane BragaNascimento, Marcia Cristina FurtadoPorto, M. Aurélia FonsecaSantos, André Luiz Muniz Alves dosCarvalho Filho, Edgar Marcelino deJesus, Amélia Maria Ribeiro de2014-02-20T23:49:19Z2014-02-20T23:49:19Z2011-11LUNA, T. et al. Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Brazilian Journal of Medical and Biological Research, Ribeirão Preto, v. 44, n. 11, nov. 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011007500140&lng=en&nrm=iso&tlng=en>. Acesso em: 20 fev. 2014.1414-431Xhttps://ri.ufs.br/handle/riufs/926Creative Commons Attribution LicenseHuman T lymphotropic virus type 1 (HTLV-1) is the causal agent of myelopathy/tropical spastic paraparesis (HAM/TSP), a disease mediated by the immune response. HTLV-1 induces a spontaneous proliferation and production of pro-inflammatory cytokines by T cells, and increasing interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) levels are potentially involved in tissue damage in diseases related to HTLV-1. This exaggerated immune response is also due to an inability of the natural regulatory mechanisms to down-modulate the immune response in this group of patients. TNF-α inhibitors reduce inflammation and have been shown to improve chronic inflammatory diseases in clinical trials. The aim of this study was to evaluate the ability of pentoxifylline, forskolin, rolipram, and thalidomide to decrease in vitro production of TNF-α and IFN-γ in cells of HTLV-1-infected subjects. Participants of the study included 19 patients with HAM/TSP (mean age, 53 ± 11; male:female ratio, 1:1) and 18 HTLV-1 carriers (mean age, 47 ± 11; male:female ratio, 1:2.6). Cytokines were determined by ELISA in supernatants of mononuclear cell cultures. Pentoxifylline inhibited TNF-α and IFN-γ synthesis with the minimum dose used (50 µM). The results with forskolin were similar to those observed with pentoxifylline. The doses of rolipram used were 0.01-1 µM and the best inhibition of TNF-α production was achieved with 1 µM and for IFN-γ production it was 0.01 µM. The minimum dose of thalidomide used (1 µM) inhibited TNF-α production but thalidomide did not inhibit IFN-γ production even when the maximum dose (50 µM) was used. All drugs had an in vitro inhibitory effect on TNF-α production and, with the exception of thalidomide, all of them also decreased IFN-γ production.Brazilian Journal of Medical and Biological ResearchHTLV-1PentoxifilinaImunologiaParaparesia espástica tropicalMielopatiaCitocinasLinfócito TNecrose tumoral alfaEffect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individualsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessTHUMBNAILEffectTNF-α.pdf.jpgEffectTNF-α.pdf.jpgGenerated Thumbnailimage/jpeg1961https://ri.ufs.br/jspui/bitstream/riufs/926/4/EffectTNF-%ce%b1.pdf.jpgbaa37b6184e05e3d2b8cc4cacb976ddfMD54ORIGINALEffectTNF-α.pdfEffectTNF-α.pdfapplication/pdf631027https://ri.ufs.br/jspui/bitstream/riufs/926/1/EffectTNF-%ce%b1.pdf659e3064c0e07bc8b266143b2d1dd7cdMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://ri.ufs.br/jspui/bitstream/riufs/926/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTEffectTNF-α.pdf.txtEffectTNF-α.pdf.txtExtracted texttext/plain32616https://ri.ufs.br/jspui/bitstream/riufs/926/3/EffectTNF-%ce%b1.pdf.txte5c8b60aa5465386cb1fd12069e25c2bMD53riufs/9262018-02-09 19:35:25.04oai:ufs.br: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2018-02-09T22:35:25Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false
dc.title.pt_BR.fl_str_mv Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
title Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
spellingShingle Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
Luna, Tânia
HTLV-1
Pentoxifilina
Imunologia
Paraparesia espástica tropical
Mielopatia
Citocinas
Linfócito T
Necrose tumoral alfa
title_short Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
title_full Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
title_fullStr Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
title_full_unstemmed Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
title_sort Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals
author Luna, Tânia
author_facet Luna, Tânia
Santos, Silvane Braga
Nascimento, Marcia Cristina Furtado
Porto, M. Aurélia Fonseca
Santos, André Luiz Muniz Alves dos
Carvalho Filho, Edgar Marcelino de
Jesus, Amélia Maria Ribeiro de
author_role author
author2 Santos, Silvane Braga
Nascimento, Marcia Cristina Furtado
Porto, M. Aurélia Fonseca
Santos, André Luiz Muniz Alves dos
Carvalho Filho, Edgar Marcelino de
Jesus, Amélia Maria Ribeiro de
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Luna, Tânia
Santos, Silvane Braga
Nascimento, Marcia Cristina Furtado
Porto, M. Aurélia Fonseca
Santos, André Luiz Muniz Alves dos
Carvalho Filho, Edgar Marcelino de
Jesus, Amélia Maria Ribeiro de
dc.subject.por.fl_str_mv HTLV-1
Pentoxifilina
Imunologia
Paraparesia espástica tropical
Mielopatia
Citocinas
Linfócito T
Necrose tumoral alfa
topic HTLV-1
Pentoxifilina
Imunologia
Paraparesia espástica tropical
Mielopatia
Citocinas
Linfócito T
Necrose tumoral alfa
description Human T lymphotropic virus type 1 (HTLV-1) is the causal agent of myelopathy/tropical spastic paraparesis (HAM/TSP), a disease mediated by the immune response. HTLV-1 induces a spontaneous proliferation and production of pro-inflammatory cytokines by T cells, and increasing interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) levels are potentially involved in tissue damage in diseases related to HTLV-1. This exaggerated immune response is also due to an inability of the natural regulatory mechanisms to down-modulate the immune response in this group of patients. TNF-α inhibitors reduce inflammation and have been shown to improve chronic inflammatory diseases in clinical trials. The aim of this study was to evaluate the ability of pentoxifylline, forskolin, rolipram, and thalidomide to decrease in vitro production of TNF-α and IFN-γ in cells of HTLV-1-infected subjects. Participants of the study included 19 patients with HAM/TSP (mean age, 53 ± 11; male:female ratio, 1:1) and 18 HTLV-1 carriers (mean age, 47 ± 11; male:female ratio, 1:2.6). Cytokines were determined by ELISA in supernatants of mononuclear cell cultures. Pentoxifylline inhibited TNF-α and IFN-γ synthesis with the minimum dose used (50 µM). The results with forskolin were similar to those observed with pentoxifylline. The doses of rolipram used were 0.01-1 µM and the best inhibition of TNF-α production was achieved with 1 µM and for IFN-γ production it was 0.01 µM. The minimum dose of thalidomide used (1 µM) inhibited TNF-α production but thalidomide did not inhibit IFN-γ production even when the maximum dose (50 µM) was used. All drugs had an in vitro inhibitory effect on TNF-α production and, with the exception of thalidomide, all of them also decreased IFN-γ production.
publishDate 2011
dc.date.issued.fl_str_mv 2011-11
dc.date.accessioned.fl_str_mv 2014-02-20T23:49:19Z
dc.date.available.fl_str_mv 2014-02-20T23:49:19Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv LUNA, T. et al. Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Brazilian Journal of Medical and Biological Research, Ribeirão Preto, v. 44, n. 11, nov. 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011007500140&lng=en&nrm=iso&tlng=en>. Acesso em: 20 fev. 2014.
dc.identifier.uri.fl_str_mv https://ri.ufs.br/handle/riufs/926
dc.identifier.issn.none.fl_str_mv 1414-431X
dc.identifier.license.pt_BR.fl_str_mv Creative Commons Attribution License
identifier_str_mv LUNA, T. et al. Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Brazilian Journal of Medical and Biological Research, Ribeirão Preto, v. 44, n. 11, nov. 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011007500140&lng=en&nrm=iso&tlng=en>. Acesso em: 20 fev. 2014.
1414-431X
Creative Commons Attribution License
url https://ri.ufs.br/handle/riufs/926
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Brazilian Journal of Medical and Biological Research
publisher.none.fl_str_mv Brazilian Journal of Medical and Biological Research
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFS
instname:Universidade Federal de Sergipe (UFS)
instacron:UFS
instname_str Universidade Federal de Sergipe (UFS)
instacron_str UFS
institution UFS
reponame_str Repositório Institucional da UFS
collection Repositório Institucional da UFS
bitstream.url.fl_str_mv https://ri.ufs.br/jspui/bitstream/riufs/926/4/EffectTNF-%ce%b1.pdf.jpg
https://ri.ufs.br/jspui/bitstream/riufs/926/1/EffectTNF-%ce%b1.pdf
https://ri.ufs.br/jspui/bitstream/riufs/926/2/license.txt
https://ri.ufs.br/jspui/bitstream/riufs/926/3/EffectTNF-%ce%b1.pdf.txt
bitstream.checksum.fl_str_mv baa37b6184e05e3d2b8cc4cacb976ddf
659e3064c0e07bc8b266143b2d1dd7cd
8a4605be74aa9ea9d79846c1fba20a33
e5c8b60aa5465386cb1fd12069e25c2b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)
repository.mail.fl_str_mv repositorio@academico.ufs.br
_version_ 1802110688812859392